top of page

ViGeneron announces research collaboration with Daiichi Sankyo

ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction of target cells via intravitreal injection that allows efficient lateral spreading and minimizes the risk of collateral damage caused by conventional subretinal injection.


Under the agreement, Daiichi Sankyo and ViGeneron will jointly conduct the first stage research and Daiichi Sankyo will have the option to negotiate a follow-on collaboration agreement for an undisclosed therapeutic target in the highly prevalent eye disease. Financial terms of the collaboration are not disclosed.


ViGeneron is dedicated to developing gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms: vgAAV gene therapy vector platform and REVeRT vector platform.


Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany. For further information, please visit www.vigeneron.com.

25 Ansichten

Aktuelle Beiträge

Alle ansehen

Die rumänische Finanzaufsichtsbehörde ASF hat die Betriebslizenz von Euroins Romania, Teil der Eurohold Bulgaria's Euroins Insurance Group,

Angesichts der komplexen Veränderungen in der Welt, in der Zeit und in der Geschichte haben die Beziehungen zwischen China und dem Iran den Prüfungen der verschiedenen internationalen Wechselfälle sta

Im Verfahren der Berliner AURICON Technische Dienste GmbH gibt es bereits wenige Wochen nach Anordnung des vorläufigen Insolvenzverfahrens eine Lösung: Nachdem das Amtsgericht Charlottenburg dem Antra

bottom of page